- Home
- Editorial
- News
- Practice Guidelines
- Anesthesiology Guidelines
- Cancer Guidelines
- Cardiac Sciences Guidelines
- Critical Care Guidelines
- Dentistry Guidelines
- Dermatology Guidelines
- Diabetes and Endo Guidelines
- Diagnostics Guidelines
- ENT Guidelines
- Featured Practice Guidelines
- Gastroenterology Guidelines
- Geriatrics Guidelines
- Medicine Guidelines
- Nephrology Guidelines
- Neurosciences Guidelines
- Obs and Gynae Guidelines
- Ophthalmology Guidelines
- Orthopaedics Guidelines
- Paediatrics Guidelines
- Psychiatry Guidelines
- Pulmonology Guidelines
- Radiology Guidelines
- Surgery Guidelines
- Urology Guidelines
Vitamin D supplementation may reduce blood sugar and metabolic syndrome risk in postmenopausal women
Vitamin D supplementation may reduce blood sugar and metabolic syndrome risk in postmenopausal women.
Supplementation with 1000 IU vitamin D may reduce blood sugar and other metabolic syndromes in postmenopausal women revealed a study published in the Journal Climacteric.
Vitamin D deficiency is associated with impaired glucose homeostasis. Association of vitamin D supplementation with various health benefits is of particular interest in nutritional research. Prior studies demonstrated that higher serum vitamin D levels were associated with a 55% reduction in the blood sugar, a 51% decreased risk of the metabolic syndrome and a 33% lower risk of cardiovascular disease (CVD).
The present study aimed at evaluating the effect of isolated vitamin D (VD) supplementation on the metabolic syndrome (MetS) risk profile in postmenopausal women.
In this double-blind, placebo-controlled trial, 160 postmenopausal women aged 50-65 years were randomized into two groups: VD group, supplementation with 1000 IU vitamin D3/day; or placebo group. The intervention time was 9 months, and the women were assessed at baseline and endpoint. Clinical and anthropometric data were collected. Biochemical parameters, including total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, glucose, and insulin, were measured. The plasma concentration of 25-hydroxyvitamin D (25(OH)D) was measured by high-performance liquid chromatography.
Key Findings
- After 9 months, there was a significant increase in the 25(OH)D levels for the VD group, and a decrease in the placebo group.
- In the Vitamin D group, a significant reduction was observed in triglycerides, insulin, and the homeostasis model assessment of insulin resistance.
- In the placebo group, there was an increase in blood sugar.
- Analysis of the risk-adjusted for age, time since menopause, and body mass index showed that women supplemented with VD had a lower risk of MetS, hypertriglyceridemia, and high blood sugar in the placebo group.
Summing up, the authors concluded that in postmenopausal women with VD deficiency, isolated supplementation with 1000 IU vitamin D3 for 9 months was associated with a reduction in the Metabolic syndrome risk profile. Women undergoing Vitamin D supplementation had a lower risk of Metabolic syndrome, hypertriglyceridemia, and hyperglycemia.
For reference, click on the link
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd